Latest Period
Q1 2026
Security Snapshot
Legend Biotech Corp - Ordinary Shares (LEGN) Institutional Ownership
CUSIP: 52490G102
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
190
Shares (Excl. Options)
96,064,508
Price
$18.09
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares
- Symbol
- LEGN on Nasdaq
- Shares outstanding
- 368,659,889
- Reported price per share
- $28.12
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 96,064,508
- Total reported value
- $1,737,614,848
- Portfolio coverage rank
- 0%
- Share change
- +8,466,161
- Value change
- +$133,068,886
- Number of holders
- 190
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- LEGN - Legend Biotech Corp - Ordinary Shares is tracked under CUSIP 52490G102.
- 190 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 196 to 190 between Q4 2025 and Q1 2026.
- Reported value moved from $1,903,820,715 to $1,737,614,848.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 190 institutions filings for Q1 2026.
Security key
52490G102
Latest holder period
Q1 2026
13F holders
190
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
LEGN full holder history
Legend Biotech Corp SEC filings
Legend Biotech Corp company facts
Legend Biotech Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 52490G102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
LEGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | -13% | $1,049,921,245 | -$147,815,434 | 48,294,445 | -12% | FMR LLC | 31 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.7% | $233,379,028 | 6,808,023 | T. Rowe Price Associates, Inc. | 31 Dec 2024 |
As of 31 Mar 2026, 190 institutional investors reported holding 96,064,508 shares of Legend Biotech Corp - Ordinary Shares (LEGN). This represents 26% of the company’s total 368,659,889 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
22%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 7% | 25,696,740 | +5.9% | 0.02% | $464,854,020 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.1% | 7,687,638 | +30% | 1.6% | $139,069,371 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2.1% | 7,581,029 | +15% | 3.7% | $137,140,815 |
| HHLR ADVISORS, LTD. | 1.6% | 5,984,550 | 0% | 6.5% | $108,260,510 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.6% | 5,763,475 | -6.5% | 0.44% | $104,261,271 |
| BlackRock, Inc. | 1.3% | 4,684,543 | +9.5% | 0% | $84,743,375 |
| Point72 Asset Management, L.P. | 1.1% | 3,886,017 | +40% | 0.12% | $70,298,048 |
| First Beijing Investment Ltd | 0.62% | 2,296,335 | 1.8% | $41,540,700 | |
| Artisan Partners Limited Partnership | 0.61% | 2,254,488 | -3.7% | 0.07% | $40,783,688 |
| TWO SIGMA INVESTMENTS, LP | 0.51% | 1,890,396 | +259% | 0.03% | $34,197,264 |
| Kynam Capital Management, LP | 0.43% | 1,576,295 | 1.8% | $28,515,177 | |
| ACADIAN ASSET MANAGEMENT LLC | 0.41% | 1,527,336 | +162% | 0.04% | $27,617,000 |
| STATE STREET CORP | 0.41% | 1,498,372 | -1.2% | 0% | $27,105,549 |
| GOLDMAN SACHS GROUP INC | 0.4% | 1,464,112 | -33% | 0% | $26,485,786 |
| Davern Capital Partners, LP | 0.36% | 1,314,748 | +24% | 6.5% | $23,783,791 |
| Patient Square Capital LP | 0.27% | 990,000 | 3.2% | $17,909,100 | |
| MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC | 0.25% | 925,920 | -3.2% | 6.8% | $16,749,893 |
| Hudson Bay Capital Management LP | 0.24% | 876,351 | +52% | 0.1% | $15,853,190 |
| JOHNSON & JOHNSON | 0.22% | 814,586 | 0% | 2.3% | $14,735,861 |
| IvyRock Asset Management (HK) Ltd | 0.22% | 804,000 | 0% | 8.2% | $14,544,360 |
| ArrowMark Colorado Holdings LLC | 0.2% | 727,144 | +0.74% | 0.35% | $13,154,035 |
| Capital International Investors | 0.18% | 647,850 | -31% | 0% | $11,719,607 |
| Triata Capital Ltd | 0.17% | 629,914 | +149% | 2.1% | $11,395,144 |
| MORGAN STANLEY | 0.16% | 603,247 | +25% | 0% | $10,912,740 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.16% | 574,898 | +20% | 0% | $10,399,905 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 96,064,508 | $1,737,614,848 | +$133,068,886 | $18.09 | 190 |
| 2025 Q4 | 87,590,750 | $1,903,820,715 | +$14,993,044 | $21.74 | 196 |
| 2025 Q3 | 83,685,243 | $2,727,887,108 | -$49,026,070 | $32.61 | 198 |
| 2025 Q2 | 84,637,633 | $3,002,800,929 | -$25,701,898 | $35.49 | 209 |
| 2025 Q1 | 85,585,612 | $2,906,390,112 | -$451,293,431 | $33.93 | 205 |
| 2024 Q4 | 99,259,008 | $3,230,144,565 | +$188,311,867 | $32.54 | 205 |
| 2024 Q3 | 91,083,902 | $4,438,353,408 | +$43,810,918 | $48.73 | 204 |
| 2024 Q2 | 91,534,759 | $4,053,943,715 | +$152,693,975 | $44.29 | 173 |
| 2024 Q1 | 86,480,093 | $4,850,469,897 | +$24,114,634 | $56.09 | 187 |
| 2023 Q4 | 85,815,138 | $5,163,245,741 | -$85,151,940 | $60.17 | 204 |
| 2023 Q3 | 85,989,090 | $5,775,420,098 | +$112,052,258 | $67.17 | 198 |
| 2023 Q2 | 84,064,242 | $5,802,906,378 | +$1,140,343,215 | $69.03 | 191 |
| 2023 Q1 | 68,026,089 | $3,279,762,243 | +$214,876,512 | $48.22 | 158 |
| 2022 Q4 | 63,494,614 | $3,169,508,515 | -$28,958,118 | $49.92 | 167 |
| 2022 Q3 | 63,810,382 | $2,603,349,501 | +$399,712,134 | $40.80 | 154 |
| 2022 Q2 | 52,707,652 | $2,898,825,468 | +$118,361,366 | $55.00 | 147 |
| 2022 Q1 | 51,010,221 | $1,853,796,102 | +$18,669,383 | $36.34 | 137 |
| 2021 Q4 | 50,201,932 | $2,340,358,513 | +$500,109,001 | $46.61 | 137 |
| 2021 Q3 | 39,005,848 | $1,971,657,000 | +$572,564,727 | $50.56 | 87 |
| 2021 Q2 | 28,328,593 | $1,162,838,000 | +$121,639,656 | $41.05 | 84 |
| 2021 Q1 | 26,391,052 | $765,864,420 | +$30,109,528 | $29.02 | 69 |
| 2020 Q4 | 25,444,505 | $716,732,000 | +$16,894,703 | $28.16 | 60 |
| 2020 Q3 | 24,479,702 | $752,680,000 | -$30,044,903 | $30.87 | 50 |
| 2020 Q2 | 24,613,241 | $1,036,097,000 | +$1,036,097,000 | $42.56 | 76 |